

# Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/M22C5D2A838AEN.html>

Date: October 2020

Pages: 86

Price: US\$ 3,500.00 (Single User License)

ID: M22C5D2A838AEN

## Abstracts

Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020

### SUMMARY

According to the recently published report 'Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020'; Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 18 molecules.

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.

The report 'Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 9 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer's Disease, Schizophrenia, Psychosis, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS),

Depression, Drug-Induced Dyskinesia, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Neurology, Presbyopia, Rett Syndrome, Sialorrhoea and Tuberos Sclerosis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)

The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects

The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development

Anavex Life Sciences Corp

AstraZeneca Plc

Cerevel Therapeutics LLC

Karuna Therapeutics Inc

Lan Sheng Biomedicine Suzhou Co Ltd

NeuroHealing Pharmaceuticals Inc

NeuroSolis Inc

Presbyopia Therapies LLC

Sosei Heptares

Suven Life Sciences Ltd

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles

(aceclidine + tropicamide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(trospium chloride + xanomeline) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

blarcamesine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVL-231 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize CHRM4 for Drug-Induced Dyskinesia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-0016878 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LS-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0527f - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0559 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0559f - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize M1 and M4 Muscarinic Acetylcholine Receptors for  
Psychosis and Cognitive Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecules to Agonize Muscarinic Acetylcholine Receptor 4 for Psychosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecules to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## tropicamide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## VU-0467154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## VU-6000918 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## VU-6001852 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products

## Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products

## Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones

## Featured News & Press Releases

Sep 10, 2020: Anavex Life Sciences announces completion of ANAVEX2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome clinical trial

Aug 19, 2020: Anavex Life Sciences announces commitment for Financial Investment by Shake It Up Foundation for Parkinson's Research for clinical trial of ANAVEX®2-73 (Blarcamesine) in patients with Parkinson's disease

Aug 05, 2020: Anavex Life Sciences receives TGA special access scheme approval for ANAVEX2-73 (blarcamesine) for Alzheimer's disease patients

Aug 03, 2020: Karuna Therapeutics announces topline data from phase 1b trial evaluating KarXT on experimentally induced pain in healthy volunteers

Jul 02, 2020: Anavex starts dosing patients in Rett syndrome trial

Jul 01, 2020: Anavex Life Sciences announces first patient dosed in EXCELLENCE Phase 2/3 clinical trial of ANAVEX<sup>®</sup>2-73 (Blarcamesine) in patients with Rett Syndrome

Jun 23, 2020: Karuna Therapeutics announces positive outcome of end-of-phase 2 meeting with the FDA for KarXT for the treatment of acute psychosis in patients with schizophrenia

Jun 16, 2020: Anavex Life Sciences announces exceeding of enrollment target for the ANAVEX 2-73 (blarcamesine) U.S. phase 2 Rett Syndrome clinical trial

Jun 04, 2020: Anavex Life Sciences receives regulatory approval from Health Canada and UK MHRA expanding phase 2b/3 ANAVEX2-73 (blarcamesine) into multinational clinical trial for Alzheimer's disease

May 27, 2020: Karuna Therapeutics to present additional data from the phase 2 clinical trial of KarXT for the treatment of psychosis in patients with schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting

Apr 23, 2020: Anavex Life Sciences announces publication of clinical data for ANAVEX2-73 (blarcamesine) in Alzheimer's Disease

Feb 24, 2020: Anavex Life Sciences announces publication of foundational data for ANAVEX2-73 (blarcamesine) in multiple sclerosis (MS)

Feb 03, 2020: Anavex Life Sciences announces Fast Track Designation granted by U.S. FDA for ANAVEX2-73 (blarcamesine) clinical development program for the treatment of Rett Syndrome

Jan 27, 2020: Anavex Life Sciences announces achievement of enrollment target for the ANAVEX2-73 (blarcamesine) phase 2 Parkinson's Disease Dementia (PDD) clinical trial

Jan 08, 2020: Anavex Life Sciences issued new U.S. patent for ANAVEX2-73 treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020  
Number of Products under Development by Therapy Areas, H2 2020  
Number of Products under Development by Indications, H2 2020  
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020  
Number of Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020 (Contd..1), H2 2020  
Products under Development by Companies, H2 2020 (Contd..2), H2 2020  
Number of Products by Stage and Mechanism of Actions, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Pipeline by Anavex Life Sciences Corp, H2 2020  
Pipeline by AstraZeneca Plc, H2 2020  
Pipeline by Cerevel Therapeutics LLC, H2 2020  
Pipeline by Karuna Therapeutics Inc, H2 2020  
Pipeline by Lan Sheng Biomedicine Suzhou Co Ltd, H2 2020  
Pipeline by NeuroHealing Pharmaceuticals Inc, H2 2020  
Pipeline by NeuroSolis Inc, H2 2020  
Pipeline by Presbyopia Therapies LLC, H2 2020  
Pipeline by Sosei Heptares, H2 2020  
Pipeline by Suven Life Sciences Ltd, H2 2020  
Dormant Projects, H2 2020  
Discontinued Products, H2 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

## I would like to order

Product name: Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/M22C5D2A838AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M22C5D2A838AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970